These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 20017910)

  • 41. Atorvastatin 10 mg plus ezetimibe versus titration to atorvastatin 40 mg: attainment of European and Canadian guideline lipid targets in high-risk subjects ≥65 years.
    Constance C; Ben-Yehuda O; Wenger NK; Zieve F; Lin J; Hanson ME; Lowe RS; Tershakovec AM
    Lipids Health Dis; 2014 Jan; 13():13. PubMed ID: 24411003
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels.
    Pearson T; Ballantyne C; Sisk C; Shah A; Veltri E; Maccubbin D
    Am J Cardiol; 2007 Jun; 99(12):1706-1713. PubMed ID: 17560879
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
    Robinson JG; Nedergaard BS; Rogers WJ; Fialkow J; Neutel JM; Ramstad D; Somaratne R; Legg JC; Nelson P; Scott R; Wasserman SM; Weiss R;
    JAMA; 2014 May; 311(18):1870-82. PubMed ID: 24825642
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia.
    Kiortisis DN; Millionis H; Bairaktari E; Elisaf MS
    Eur J Clin Pharmacol; 2000 Dec; 56(9-10):631-5. PubMed ID: 11214768
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of ezetimibe on cholesterol subfractions in dyslipidemic cardiac transplant recipients receiving statin therapy.
    Le VV; Racine N; Pelletier GB; Carrier M; Cossette M; White M
    Clin Transplant; 2009; 23(2):249-55. PubMed ID: 19402219
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?
    Piorkowski M; Fischer S; Stellbaum C; Jaster M; Martus P; Morguet AJ; Schultheiss HP; Rauch U
    J Am Coll Cardiol; 2007 Mar; 49(10):1035-42. PubMed ID: 17349882
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients.
    Costet P; Hoffmann MM; Cariou B; Guyomarc'h Delasalle B; Konrad T; Winkler K
    Atherosclerosis; 2010 Sep; 212(1):246-51. PubMed ID: 20619837
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease.
    Rosen JB; Jimenez JG; Pirags V; Vides H; Hanson ME; Massaad R; McPeters G; Brudi P; Triscari J
    Diab Vasc Dis Res; 2013 May; 10(3):277-86. PubMed ID: 23288881
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ezetimibe plus fenofibrate: a new combination therapy for the management of mixed hyperlipidaemia?
    Farnier M
    Expert Opin Pharmacother; 2007 Jun; 8(9):1345-52. PubMed ID: 17563268
    [TBL] [Abstract][Full Text] [Related]  

  • 50. LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD.
    McKenney J; Ballantyne CM; Feldman TA; Brady WE; Shah A; Davies MJ; Palmisano J; Mitchel YB
    MedGenMed; 2005 Jul; 7(3):3. PubMed ID: 16369229
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Influence of age, gender, and race on the efficacy of adding ezetimibe to atorvastatin vs. atorvastatin up-titration in patients at moderately high or high risk for coronary heart disease.
    Bays HE; Conard SE; Leiter LA; Bird SR; Lowe RS; Tershakovec AM
    Int J Cardiol; 2011 Dec; 153(2):141-7. PubMed ID: 20837371
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of the effects of combination atorvastatin (40 mg) + ezetimibe (10 mg) versus atorvastatin (40 mg) alone on secretory phospholipase A2 activity in patients with stable coronary artery disease or coronary artery disease equivalent.
    Azar M; Valentin E; Badaoui G; Kassab R; Sarkis A; Azar RR
    Am J Cardiol; 2011 Jun; 107(11):1571-4. PubMed ID: 21439529
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of coadministered ezetimibe plus fenofibrate in mixed dyslipidemic patients with metabolic syndrome.
    Bays HE; Shah A; Macdonell G; Taggart WV; Gumbiner B
    Metab Syndr Relat Disord; 2011 Apr; 9(2):135-42. PubMed ID: 21117970
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial.
    Davidson M; Rosenson RS; Maki KC; Nicholls SJ; Ballantyne CM; Setze C; Carlson DM; Stolzenbach J
    Cardiovasc Drugs Ther; 2012 Aug; 26(4):349-58. PubMed ID: 22622962
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) Study.
    Galin ID; Smith DA
    Am Heart J; 2006 May; 151(5):e1. PubMed ID: 16644302
    [No Abstract]   [Full Text] [Related]  

  • 56. Effectiveness of low-intensity atorvastatin 5 mg and ezetimibe 10 mg combination therapy compared with moderate-intensity atorvastatin 10 mg monotherapy: A randomized, double-blinded, multi-center, phase III study.
    Lee SA; Hong SJ; Sung JH; Kim KS; Kim SH; Cho JM; Chun SW; Lee SR; Kim CS; Kim TN; Kim DH; Park HC; Kim BJ; Kim HS; Choi JY; Hong YJ; Chung JW; Yoon SB; Lee SH; Lee CW
    Medicine (Baltimore); 2023 Nov; 102(47):e36122. PubMed ID: 38013289
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study.
    Derdemezis C; Filippatos T; Tselepis A; Mikhailidis D; Elisaf M
    Expert Opin Pharmacother; 2008 Aug; 9(11):1829-37. PubMed ID: 18627322
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemia.
    Teramoto T; Takeuchi M; Morisaki Y; Ruotolo G; Krueger KA
    Am J Cardiol; 2014 Jun; 113(12):2021-9. PubMed ID: 24786356
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study.
    Farsang C; Athyros V; Gaw A;
    Curr Med Res Opin; 2007 Aug; 23(8):1945-56. PubMed ID: 17626713
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.
    Goldberg AC; Bays HE; Ballantyne CM; Kelly MT; Buttler SM; Setze CM; Sleep DJ; Stolzenbach JC
    Am J Cardiol; 2009 Feb; 103(4):515-22. PubMed ID: 19195513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.